The content on this site is intended for healthcare professionals only
Dr Martin Hutchings speaks to ecancer about the 5-year update of the ECHELON-1 trial. It is an international, open-label, randomised, phase 3 trial. Initially,
Dr Hutchings mentions the rationale of this study. He then explains the key results from this trial. The ECHELON-1 study assessed the safety and efficacy of front-line A+AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) in patients with stage III or IV classical Hodgkin lymphoma. The primary analysis showed improved modified progression-free survival with A+AVD. In the end, he talks about the impact of these results on the future treatment of Hodgkin lymphoma.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Multiple Myeloma: evolving paradigm - Panel Discussion
Advancements in paediatric Acute lymphoblastic leukemia management
Choosing 1st line TKI Wisely in patients with CML
Multiple myeloma In Rwanda: The need for further research
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia
Ponatinib is better than imatinib for frontline treatment of newly diagnosed Ph+ acute lymphoblastic leukaemia
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
